The complement cascade in lung injury and disease

Respiratory Research

Table 1 Complement-targeted therapeutics in lung disease

Name	Target	Type	Indication	Company	References
Eculizumab (Soliris®)	C5	mAb	COVID-19	Alexion	[157,158,159]
Vilobelimab	C5a	mAb	COVID-19, cutaneous squamous cell carcinoma	InflaRx	[156, 163, 164]
AMY-101	C3	compstatin peptide	COVID-19	Amyndas Pharmaceuticals	[160,161,162]
Narsoplimab	MASP-2	mAb	COVID-19	Omeros	[165]
Avdoralimab	C5aR1	mAb	Solid tumours, non-small cell lung cancer	Innate Pharma	[142]

ISSN: 1465-993X